Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT
Clinical trial NCT01232504 · COMPLETED
Trial details
- NCT number
- NCT01232504
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2009-09-01
- Primary completion
- 2013-03-01
- Enrollment
- 206
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.